The first article in this supplement is an overall review of the first glycylcycline, tigecycline, which includes a brief overview of the problem of tetracycline resistance as well as tigecycline's mode of action, antibacterial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability. The remaining articles in the supplement report the European clinical experience from the pivotal clinical trials in complicated intra-abdominal infections, complicated skin and skin structure infections and community acquired pneumonia.